Stock FDMT 4D MOLECULAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
27.22 USD +5.54% Intraday chart for 4D Molecular Therapeutics, Inc. +28.70% +34.35%
Jun. 24 4D Molecular Therapeutics Says US FDA Clears its IND Application for Potential Geographic Atrophy Treatment MT
Jun. 24 4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
4D Molecular Therapeutics Says US FDA Clears its IND Application for Potential Geographic Atrophy Treatment
MT
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
GL
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
CI
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
GL
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
AQ
Transcript : 4D Molecular Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
AQ
4D Molecular Therapeutics, Inc. Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
CI
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
GL
Transcript : 4D Molecular Therapeutics, Inc. - Special Call
4D Molecular Therapeutics : 710 AEROW Phase 1/2 Interim Clinical Data – June 2024
PU
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
GL
4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis At 47Th European Cystic Fibrosis Conference
CI
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
GL
4DMT to Participate in Upcoming Investor Conferences
GL
4DMT to Participate in Upcoming Investor Conferences
AQ
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
GL
Transcript : 4D Molecular Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FDMT Stock
  4. News 4D Molecular Therapeutics, Inc.